Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses hair loss treatments using oral minoxidil, oral dutasteride, and mesotherapy dutasteride, showing impressive 6-month results. The user wishes these treatments were available in the U.S.

miR-205, a tiny RNA, can stimulate hair growth by softening aging hair follicle stem cells in mice. Future tests aim to see if this can work in humans.

Hair loss treatments like finasteride, minoxidil, and dutasteride are discussed, with users sharing mixed experiences about effectiveness and side effects. Some users report positive results, while others express concerns about side effects, highlighting the importance of personal choice.

A user plans to switch from finasteride to dutasteride for better hair loss treatment, citing dutasteride's higher DHT suppression. Others share mixed experiences, discussing transition methods, shedding, and potential side effects.

Hopeful treatments for hair loss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.

Men should feel socially accepted wearing hair systems, similar to how women use extensions and makeup. Treatments mentioned include minoxidil, finasteride, and hair transplants.

A user shared their positive experience of embracing baldness after years of trying treatments like Minoxidil and finasteride. They found happiness and confidence by shaving their head, despite some social challenges, and encouraged others to focus on their attitude and seek therapy if needed.

A user is considering creating an all-in-one topical solution for hair loss, combining 0.25mg finasteride, 5% minoxidil, and 5% RU58841. They are seeking advice on its feasibility and absorption.

The conversation discusses using dutasteride, both topical and oral, for hair loss in trans men, considering potential side effects like depression and libido issues. The user is exploring options including topical solutions with minoxidil, retinoic acid, and hydrocortisone, and plans to start microneedling.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

Redensyl, which is a topical alternative to Minoxidil for hair loss. It may have advantages such as not making the hair greasy and lasting longer after discontinuing use than minoxidil. There are some positive reports from users, but also some negative ones, so it's unclear how effective this treatment will be in comparison to Minoxidil and other treatments like Finasteride or RU58841.

A user ordered a compounded medication from Musely containing Dutasteride, Minoxidil, and other vitamins, expressing concerns about its contents and effectiveness. Another user shared their experience with side effects but noted hair regrowth, while adjusting the dosage to reduce symptoms.

The user reported noticeable hair improvement over four months using 1 mg of finasteride and weekly microneedling. Progress photos from October 2024 to January 2025 show positive changes.

User asks if Kintor, HMI-115, or Olix will release hair loss drugs in 2023. Conversation discusses potential treatments and release dates.

The post discusses a user's experience with hair loss treatments, specifically topical finasteride, minoxidil, and micro-needling, and their plan to switch to oral versions and add Dutasteride. The conversation includes various responses, with some users sharing their own experiences and side effects, and others expressing desire for a more permanent hair loss solution.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It mentions a CEO becoming the first patient for HairClone.

The conversation discusses the lack of experiments combining verteporfin and microneedling for hair loss treatment. The user expresses interest in participating in a group buy to try this method.

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

The conversation is about the progress of verteporfin in hair loss trials, with users expressing curiosity about its effectiveness and updates. Specific treatments mentioned include FUE (Follicular Unit Extraction) combined with verteporfin, with one reported case of donor area regrowth after a year, and three patients being monitored post-treatment by Dr. Bloxham with monthly updates on YouTube.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

The conversation discusses the potential of using topical estrogen treatments for hair loss without systemic absorption, highlighting challenges and possible solutions like using estriol. It also mentions other treatments like topical finasteride, microneedling, and scalp massage, while noting the limitations and side effects of current options.

A human trial of verteporfin, a potential treatment for hair loss, with some users noting potential improvements in scarring and overall healing compared to control areas.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

HairClone aims to rejuvenate miniaturizing hair follicles through follicle banking and cell expansion, with treatments potentially available in the UK by 2022. The process involves extracting, storing, and cloning hair follicles, but full regenerative treatments will take many years to develop.

People are discussing hair loss treatments and expressing hope for future hair cloning. Some mention using Minoxidil, finasteride, and RU58841.

The conversation is about seeking recommendations for clinics in Los Angeles that offer dutasteride mesotherapy for hair loss treatment. The user is asking for experiences and suggestions from the community.

The user experienced significant hair and beard regrowth using 0.5mg dutasteride and 5mg oral minoxidil over a year, despite initial shedding. They reported no major side effects, except for increased body hair growth.

Finasteride and dutasteride may increase estrogen levels, leading to water retention and a fuller face. Users discuss managing these effects with lifestyle changes and supplements like zinc and DIM.

A European individual planning to go to China is seeking information on how to participate in HMI-115 trials for Androgenetic Alopecia. They've tried contacting Mrs. Yang and Mr. Wang for assistance but haven't received a response.

The conversation discusses the potential availability of GT20029 for hair loss treatment, with one user noting promising Phase 1 results and inquiring about gray market access. Another user humorously suggests it will take 50 years to become available.